Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Tocagen Inc (TOCA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 147,924
  • Shares Outstanding, K 23,782
  • Annual Sales, $ 18,040 K
  • Annual Income, $ -48,960 K
  • 60-Month Beta 3.79
  • Price/Sales 8.20
  • Price/Cash Flow N/A
  • Price/Book 3.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.75
  • Number of Estimates 3
  • High Estimate -0.69
  • Low Estimate -0.82
  • Prior Year -0.81
  • Growth Rate Est. (year over year) +7.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.13 +40.19%
on 05/28/19
9.27 -37.54%
on 05/17/19
-3.14 (-35.16%)
since 05/14/19
3-Month
4.13 +40.19%
on 05/28/19
11.30 -48.76%
on 03/20/19
-4.69 (-44.75%)
since 03/14/19
52-Week
4.13 +40.19%
on 05/28/19
15.80 -63.35%
on 10/02/18
-3.65 (-38.67%)
since 06/14/18

Most Recent Stories

More News
Tocagen's Toca 5 Pivotal Phase 3 Clinical Trial in Patients with Recurrent Brain Cancer Continues Without Modification at Planned Interim Analysis

Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced the Toca 5 Phase 3 clinical trial evaluating Toca 511 & Toca FC in patients with recurrent high grade...

TOCA : 5.79 (-6.91%)
Notable Tuesday Option Activity: TOCA, NAV, CMG

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Tocagen Inc , where a total volume of 6,626 contracts has been traded thus far today,...

TOCA : 5.79 (-6.91%)
Tocagen Reports First Quarter 2019 Financial and Business Results

Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the first quarter ended March 31, 2019.

TOCA : 5.79 (-6.91%)
Investor Expectations to Drive Momentum within GoDaddy, MDU Resources Group, Enerplus, Quorum Health, Resonant, and TOCAGEN INC -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of GoDaddy Inc. (NYSE:GDDY), MDU...

GDDY : 70.04 (-1.42%)
ERF : 6.55 (-3.82%)
RESN : 2.49 (-3.11%)
QHC : 1.54 (-6.67%)
TOCA : 5.79 (-6.91%)
MDU : 25.86 (+0.70%)
Tocagen Appoints Fairooz Kabbinavar, M.D., FACP, as Senior Vice President, Clinical Development

Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced the appointment of Fairooz Kabbinavar, M.D., FACP, as senior vice president, clinical development....

TOCA : 5.79 (-6.91%)
Tocagen to Present Updated Data from Clinical and Preclinical Studies at Two Scientific Conferences

Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced three presentations of updated clinical and preclinical data at the American Association for Cancer...

TOCA : 5.79 (-6.91%)
Advanced Medical Technologies Provide Unprecedented Targeting in Cancer Therapy

Pharmaceutical companies are now employing advanced medical breakthroughs and new technologies, including gene therapies and nanoparticle engineering, to fight every type of cancer.

NVS : 89.52 (-0.08%)
BOLD : 37.95 (-1.04%)
PFE : 42.76 (+0.61%)
TOCA : 5.79 (-6.91%)
GNPX : 1.35 (-6.03%)
Implied Volatility Surging for Tocagen (TOCA) Stock Options

Investors need to pay close attention to Tocagen (TOCA) stock based on the movements in the options market lately.

TOCA : 5.79 (-6.91%)
Tocagen Reports Fourth Quarter and Full Year 2018 Financial and Business Results

Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2018....

TOCA : 5.79 (-6.91%)
Tocagen to Report Fourth Quarter and Full Year Financial Results on Wednesday, February 27 and Present at Upcoming SVB Leerink Global Healthcare Conference

Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced it will report its fourth quarter and full year 2018 financial results and business progress on Wednesday,...

TOCA : 5.79 (-6.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade TOCA with:

Business Summary

Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The company's lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need....

See More

Key Turning Points

2nd Resistance Point 6.42
1st Resistance Point 6.10
Last Price 5.79
1st Support Level 5.57
2nd Support Level 5.35

See More

52-Week High 15.80
Fibonacci 61.8% 11.34
Fibonacci 50% 9.97
Fibonacci 38.2% 8.59
Last Price 5.79
52-Week Low 4.13

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar